摘要目的:研究肝母细胞瘤HUH-6株与正常肝LO2细胞株microRNA-21及其靶基因PDCD4和PTEN表达的差别；研究抑制microRNA-21表达后肝母细胞瘤HUH-6细胞株中microRNA-21及其靶基因PDCD4和PTEN的变化，以及反义抑制后HUH-6细胞凋亡、细胞增殖周期的变化。方法:正常肝LO2细胞株与肝母细胞瘤HUH-6株作为研究对象，将肝母细胞瘤HUH-6细胞株分为3组，包括：空白对照组(正常培养的HUH-6细胞)；microRNA-21抑制组(转染microRNA-21抑制序列的细胞)；阴性对照组(转染无关序列的HUH-6细胞)。运用实时荧光定量PCR技术分析各组细胞中的microRNA-21的表达水平。运用流式细胞技术检测反义抑制microRNA-21后HUH-6细胞凋亡以及细胞增殖情况。用Westen-blot检测细胞中PDCD4和PTEN的表达情况。结果:与正常肝LO2细胞株相比，肝母细胞瘤HUH-6株microRNA-21表达上调；反义抑制后HUH-6细胞中microRNA-21表达下降；反义抑制后HUH-6细胞增殖率下降，凋亡率增加；反义抑制后HUH-6细胞PDCD4和PTEN表达增加。结论:本研究通过细胞实验，发现肝母细胞瘤瘤细胞中microRNA-21表达上调，并可以负性调节靶基因蛋白PDCD4及PTEN蛋白的表达；microRNA-21可能通过PDCD4及PTEN蛋白调节肝母细胞瘤的增殖与凋亡。本研究首次进行microRNA-21在肝母细胞瘤细胞中的表达研究，为microRNA-21及靶基因PDCD4及PTEN在肝母细胞瘤发病机制的研究奠定基础，在肝母细胞瘤的治疗方面具有光明的研究前景。

abstractsObjective:To explore the differential expression of HUH6 cell microRNA-21 with normal hepatocellular LO2 and its target genes of PDCD4/PTEN, and to detect the changes of antisense inhibition and cell proliferation cycle.Methods:Cells were divided into four groups of LO2 (normal liver cell), HUH-6NC (unprocessed cell), HUH-6 ASODN (transfection with ASODN) and HUH 6-AM (transfection with negative ASOD). Quantitative polymerase chain reaction (PCR) was employed for detecting the expression level of microRNA-21 in each cell group. Flow cytometry was utilized for analyzing antisense apoptosis and cell proliferation. Westent blot was employed for measuring the expressions of PDCD4 and PTEN.Results:Compared with LO2 group, the expression of microRNA-21 increased in HUH6 group. After antisense inhibition, there was a lower expression of microRNA-21 in HUH-6 group. After antisense inhibition, the proliferating rate of HUH-6 cell decreased while apoptotic rate rose. After antisense inhibition, the expressions of PDCD4 and PTEN decreased in HUH-6 group.Conclusions:An up-regulation of microRNA-21 negatively adjusts target gene PDCD4 and PTEN in tumor cells. And PDCD4/PTEN protein may be employed for adjusting the proliferation and apoptosis of HB. The expression of microRNA-21 is associated with clinical stage. It has bright prospects for hepatoblastoma treatment.